论文部分内容阅读
目的 探讨CD44变异剪接体 6(CD44V6 )在甲状腺肿瘤组织的表达情况及其与肿瘤发生、发展、浸润和转移的关系。方法 采用免疫组织化学S P法检测 2 0例癌旁甲状腺组织 ,2 4例甲状腺腺瘤和 64例甲状腺癌的石蜡标本CD44V6 表达水平。结果 CD44V6 在甲状腺腺癌的表达率 ( 92 19%)显著高于甲状腺腺瘤者 ( 5 8 3 3 %,P <0 0 1) ,癌旁甲状腺组织未见表达。甲状腺中不同组织来源的滤泡细胞癌和髓样癌的CD44V6 表达差异具有显著性 ,总阳性率分别为 96 5 5 %及 5 0 0 %(P <0 0 1)。但CD44V6 表达水平在乳头状腺癌和滤泡型腺癌间差别无显著性 (P >0 0 5 )。同时发现 2例未分化癌CD44V6 表达均呈强阳性。CD44V6 的表达水平与甲状腺癌的包膜浸润和淋巴结转移有关 ,CD44V6 表达水平在包膜浸润组和未浸润组之间 ,在淋巴结转移组和非转移组之间差别有显著性 (P <0 0 1)。CD44V6 表达与患者年龄、性别、肿瘤的大小无关 (P >0 0 5 )。结论 CD44V6 的表达与甲状腺肿瘤的分化和浸润、转移显著相关 ,检测CD44V6 有助于甲状腺癌的诊断、判断预后并可能为甲状腺癌的手术和术后综合治疗决策提供新的分子生物学指标。
Objective To investigate the expression of CD44 variant spliceosome 6 (CD44V6) in thyroid tumors and its relationship with tumorigenesis, development, invasion and metastasis. Methods The expression of CD44V6 in paraffin-embedded thyroid tissue, 24 thyroid adenomas, and 64 thyroid cancer specimens was detected by immunohistochemistry SP method. Results The expression rate of CD44V6 in thyroid adenocarcinoma (92 19%) was significantly higher than that of thyroid adenoma (58.33%, P < 0.01). There was no expression of parathyroid thyroid tissue. The differential expression of CD44V6 in follicular cell carcinoma and medullary carcinoma from different tissues in the thyroid gland was statistically significant, with a total positive rate of 96.5% and 500% (P < 0.01). However, there was no significant difference in the expression of CD44V6 between papillary adenocarcinoma and follicular adenocarcinoma (P > 0.05). At the same time, the expression of CD44V6 in two cases of undifferentiated carcinoma was strongly positive. The expression level of CD44V6 was related to thyroid cancer capsule infiltration and lymph node metastasis. The expression of CD44V6 was in the infiltrating and non-infiltrating groups, and there was a significant difference between the lymph node metastasis group and the non-metastatic group (P <0 0). 1). The expression of CD44V6 was not related to the patient’s age, gender, and tumor size (P > 0.05). Conclusion The expression of CD44V6 is significantly associated with the differentiation, invasion and metastasis of thyroid tumors. The detection of CD44V6 is helpful for the diagnosis and prognosis of thyroid cancer and may provide new molecular biological indicators for thyroid cancer surgery and postoperative comprehensive treatment decisions.